Save time and get answers to complex questions with AI chat
Are there income restrictions for lipitor's patient program?Dabrafenib mesylate when the patent is expiring in india?Tracleer online pharmacy?Prolia and osteonecrosis?Is it okay to take anti histamine when on statins?
See the DrugPatentWatch profile for Ustekinumab
Short answer (as of my last update in 2024): - EU launch of ustekinumab (Stelara) biosimilars: None had launched in Europe yet. Several biosimilar candidates were in late-stage development or regulatory review, but a market entry date in the EU had not been established by mid-2024. Launch timing will depend on patent expiry and regulatory approvals, so any date is uncertain and country-dependent. - Stelara patent expiry in Europe: The patent landscape for ustekinumab in Europe is complex, with multiple patent families and data/ SPC protections. There isn’t a single Europe-wide expiry date. Some core patents may have expired in some jurisdictions by the early-to-mid 2020s, but additional protections (SPCs and other patents) can extend exclusivity in various EU markets. For a precise expiry date, you’d need to look up the specific patent families in the European Patent Register and confirm the SPC status in each EU country. If you’d like, I can look up the latest, country-by-country patent expiry dates and the current status of EU biosimilar applications. Just tell me and I’ll fetch the most up-to-date sources.
Other Questions About Ustekinumab :